The actions of the anticonvulsant gabapentin [1-(aminomethyl)-cyclohexaneacetic acid, Neurontin] have been somewhat enigmatic until recently, when it was claimed to be a ␥-aminobutyric acid-B (GABA B ) receptor agonist acting exclusively at a heterodimeric complex containing the GABA B(1a) splice variant (Mol Pharmacol 2001;59:144 -152). In this study, we have investigated the effects of gabapentin on recombinant GABA B(1a) and GABA B(1b) receptors coexpressed with GABA B(2) in five different functional recombinant assays, its ability to inhibit [ 3 H]GABA binding in a GABA B receptor-selective binding assay using rat synaptic membranes, and its ability to inhibit transient lower esophageal sphincter relaxations in Labrador retriever dogs. Up to a concentration of 1 mM, gabapentin displayed no agonistic effects on either the GABA B(1a,2) or the GABA B(1b,2) heterodimer, when these were expressed in Xenopus laevis oocytes or mammalian cells and assayed by means of electrophysiology, calcium mobilization, inositol phosphate, and fluorometry assays. Gabapentin did not displace [
␥-Aminobutyric acid (GABA) is the major inhibitory neurotransmitter in the central nervous system, where it exerts its effect through the ionotropic GABA A receptors and the metabotropic GABA B receptors. The GABA B receptors belong to the family C of the G-protein-coupled receptor superfamily (Möhler and Fritschy, 1999; Marshall et al., 2000) . Two receptors, GABA B(1) and GABA B(2) , have recently been cloned, and several splice variants of both receptors have been identified (Kaupmann et al., 1997 (Kaupmann et al., , 1998 Jones et al., 1998; White et al., 1998; Pfaff et al., 1999; Billinton et al., 2001) .
GABA B(1) and GABA B(2) form heterodimers (Jones et al., 1998; Kaupmann et al., 1998; White et al., 1998) . Gene knockout studies have shown that GABA B(1) is a necessary part for virtually all central GABA B receptors (Prosser et al., 2001; Schuler et al., 2001) . The majority of the GABA B heterodimer complexes are either of a GABA B(1a,2) or a GABA B(1b,2) composition, and the two GABA B(1) splice variants differ in their expression pattern and their pre-and postsynaptic localization (Kaupmann et al., 1997; Benke et al., 1999; Poorkhalkali et al., 2000; Prosser et al., 2001; Schuler et al., 2001) . Agonist binding to the GABA B(1,2) heterodimer has been demonstrated to take place in the amino-terminal domain of the GABA B(1) subunit (Galvez et al., 1999 (Galvez et al., , 2000 Malitschek et al., 1999) . The major part of this region shares a weak amino acid sequence similarity with a family of bacterial periplasmic binding proteins, as is the case for other family C receptors such as the metabotropic glutamate receptors and the calcium-sensing receptor (O'Hara et al., 1993; Kaupmann et al., 1997; Brä uner-Osborne et al., 1999b) . This "Venus flytrap" (VFT) region is believed to consist of two globular lobes, and the endogenous agonist binds to residues in the cleft between these lobes (Galvez et al., 1999 (Galvez et al., , 2000 Kunishima et al., 2000) . The VFT region is conserved in its entirety in all GABA B(1) splice variants. Thus, the only molecular difference between splice variants GABA B(1a) and GABA B(1b) is the presence of two "Sushi domains" upstream of the VFT region in GABA B(1a) that are not found in GABA B(1b) (Kaupmann et al., 1997) . The human GABA B(1c) is characterized by the absence of the second Sushi domain compared with GABA B(1a) (Billinton et al., 2001) .
Gabapentin [1-(aminomethyl) cyclohexaneacetic acid, Neurontin] is a frequently administered anticonvulsant that has been shown to prevent partial seizures and generalized tonicclonic seizures in epileptics (Taylor et al., 1998) . Furthermore, the compound has displayed promising results in animal models of various forms of pain, amyotrophic sclerosis, bipolar disorder, and anxiety (Taylor et al., 1998) . Although it was developed as an analog of GABA, gabapentin was originally claimed not to interact directly with either GABA A or GABA B receptors or with the high-affinity Na ϩ -dependent GABA transporters (Taylor, 1995; Taylor et al., 1998) . Thus, the site of action of gabapentin has been somewhat of an enigma, although the compound displays high-affinity binding to the ␣ 2 ␦ subunit of a calcium channel (Gee et al., 1996; Marais et al., 2001) .
In contrast to the previous beliefs, Ng et al. (2001) recently claimed that gabapentin is, in fact, a GABA B receptor agonist. Furthermore, the authors postulated that gabapentin acts exclusively on the GABA B(1a,2) heterodimer complex and has no effect on the GABA B(1b,2) and GABA B(1c,2) heterodimers . Therefore, gabapentin is the first GABA B receptor splice variant-selective compound to be identified in a published study. The GABA B(1a,2) activity of gabapentin was supported by a follow-up study in which the compound was reported to inhibit the high K ϩ -evoked activation of voltage-dependent calcium channels in a murine mIL-tsA58 cell line that endogenously expresses the GABA B(1a,2) heterodimer .
The proposed splice variant selectivity of gabapentin is quite remarkable, considering that the "Sushi domains" differentiating the GABA B(1) splice variants are located outside of the VFT region responsible for the binding of the endogenous agonist. Hence, to elucidate these observations further, we have characterized gabapentin pharmacologically at GABA B(1a,2) and GABA B(1b,2) heterodimers in five different functional recombinant assays, in a [ 3 H]GABA binding assay to rat synaptic membranes, and in a model measuring transient lower esophageal sphincter relaxations (TLESRs) in dogs.
Experimental Procedures
Materials. Culture media, serum, antibiotics, and buffers for cell culture were obtained from Invitrogen (Paisley, Scotland, UK). 3.4-(2-Aminoethyl)benzenesulfonylfluoride (AEBSF) was obtained from Calbiochem (La Jolla, CA). The gabapentin used in the study was obtained from Sigma-Aldrich (St. Louis, MO) or from Goedecke/ Parke-Davis (Freiburg, Germany) (hereafter termed "Goedecke"), or it was extracted from Neurontin 100 capsules (Pfizer, New York, NY Electrophysiology on Oocytes. Oocyte preparation and injection were done essentially as described previously Lingenhoehl et al., 1999) . In brief, ovarian lobes containing oocytes were surgically removed from anesthetized (1.2 g/l 3-aminobenzoic acid ethyl ester) female Xenopus laevis frogs. Oocytes were separated and defolliculated by treatment with collagenase type II (Sigma-Aldrich) and with a subsequent incubation in 4 mM EGTA, pH 8.5. They were injected 3 h later with 10 to 50 ng of mRNA coding for either of the two rat splice variants GABA B(1a) or GABA B(1b) (Kaupmann et al., 1997) , together with GABA B(2) and rat inwardly rectifying potassium channels (Kir3.1, Kir3.2, and Kir3.4), and incubated at 18°C for 3 to 8 days. Two-electrode voltage-clamp recordings were made with a Geneclamp 500 amplifier (Axon Instruments, Union City, CA) using electrodes filled with 3 M KCl. Oocytes were continuously perfused with normal frog Ringer (115 mM NaCl, 10 mM HEPES, 2.5 mM KCl, and 1.8 mM CaCl 2 , pH 7.2) or highpotassium Ringer (90 mM KCl, 27.5 mM NaCl, 10 mM HEPES, and 1.8 mM CaCl 2 , pH 7.2). The compounds were dissolved in water at 100 mM and perfused in high-potassium Ringer at the given concentrations. No corrections for changes in the osmolarity were performed. Currents were recorded using LabVIEW-based software (KooL; New Vision Engineering, Winterthur, Switzerland) and analyzed using Prism 3.0 software (GraphPad, San Diego, CA). Baseline current drifts were corrected using linear interpolations. For concentration-response curves, the induced inward current was measured 2 s before the application of the next higher concentration. Data from different oocytes were pooled. Values are mean Ϯ S.E.M.
Measurement of [Ca 2؉ ] i by Fluorescence Imaging Plate Reader. For measurement of changes in intracellular calcium concentrations, human embryonic kidney (HEK) 293 cells were transiently transfected with rat or human GABA B(1a,2) or GABA B(1b,2) . All transfections included G␣qzic to couple the receptors to phospholipase C (Franek et al., 1999 ) and were made as described in detail previously (Pagano et al., 2001) . Transfected HEK 293 cells were plated into poly(D-lysine)-coated 96-well plates (BD Biosciences, San Jose, CA). At 24 to 72 h after transfection, cells were loaded for 45 min with 2 M fluo-4 acetoxymethyl ester (Molecular Probes, Eugene, OR) in Hanks' buffered saline solution (HBSS) (Invitrogen, Basel, Switzerland) containing 50 M probenecid (Sigma-Aldrich, Buchs, Switzerland). Plates were washed twice in HBSS and transferred to a FLIPR (Molecular Devices, Crawley, UK). Fluorescence was measured at room temperature for 3 min after the addition of agonists. Relative fluorescence changes over baseline (⌬F/F) were determined. Concentration-response curves were recorded with three to eight wells per concentration and experiment, and the data were pooled and fitted using Igor Pro (Wavemetrics, Lake Oswego, OR) with a logistic equation using weighted nonlinear regression.
The abilities of GABA and gabapentin to evoke changes in the intracellular calcium concentrations were also measured in Chinese hamster ovary (CHO-K1) cells stably expressing GABA B(1a) and GABA B(2) and in CHO-K1 cells stably expressing a GABA B(1a) -G␣q-i5 fusion protein and GABA B(2) . Fusion proteins of G-protein-coupled receptors and G-proteins have been demonstrated in numerous studies to exhibit pharmacological profiles similar to those of the wildtype receptors (Seifert et al., 1999) . The cells were assayed in a FLIPR (Molecular Devices, Menlo Park, CA), using procedures similar to those described above.
Calcium Measurements by Fluorometer. HEK 293 cells (1.5 ϫ 10 6 ) were electroporated (250 V, 300 F; Gene Pulser; Bio-Rad, Hercules, CA) with 5 g of rat GABA B(1a) or GABA B(1b) cDNA with 1378 GABA B(2) and G␣qzic (Franek et al., 1999) cDNAs in a total volume of 150 l of buffer (50 mM K 2 HPO 4 , 20 mM CH 3 COOK, and 20 mM KOH, pH 7.4). Transfected cells were resuspended in culture medium and plated on poly(D-lysine)-coated glass coverslips. Twentyfour hours after transfection, the cells were incubated at room temperature for 1 h in a HEPES buffer, pH 7.6 (Invitrogen), containing the calcium indicator fura-2 acetoxymethyl ester (10 g/ml), 0.5% Pluronic F-127 (Molecular Probes), and 1% (v/v) dimethyl sulfoxide. Glass coverslips carrying dye-loaded cells were mounted into a perfusing cuvette (2 ml/min) in a fluorescence spectrophotometer (F-4500; Hitachi, Yokohama, Japan). Changes in [Ca 2ϩ ] i were recorded as the fluorescence ratio at 380 nm versus that at 360 nm. The viability of transfected cells was tested by application of 10 M ATP.
Inositol Phosphate Assay. The tsA cells [a transformed HEK 293 cell line (Chahine et al., 1994) ] were maintained at 37°C in a humidified 5% CO 2 incubator in Dulbecco's modified Eagle's medium supplemented with 100 U/ml penicillin, 100 g/ml streptomycin, and 10% calf serum. tsA cells (3 ϫ 10 5 ) were plated in a 6-cm tissue culture plate and transfected the following day with 0.25 g of GABA B(1a) -pCDNA3.1 or GABA B(1b) -pCDNA3.1, 1.2 g of GABA B(2) -pCDNA3.1, and 0.25 g of G␣q-z5-pCDNA3.1, using Polyfect as DNA carrier according to the protocol of the manufacturer (QIAGEN GmbH, Hilden, Germany). The day after transfection, the cells were transferred to 24 wells in a 96-well cluster plate in growth medium containing 2 Ci/ml myo- [2- 3 H]inositol. After 16 to 20 h, the cells were washed in HBSS and incubated for 20 min in HBSS supplemented with 0.9 mM CaCl 2 and 1.05 mM MgCl 2 . The cells were then incubated for another 20 min in phosphate-buffered saline supplemented with 0.9 mM CaCl 2 , 1.05 mM MgCl 2 , and 10 mM LiCl. Finally, the cells were incubated for 40 min in phosphate-buffered saline supplemented with 0.9 mM CaCl 2 , 1.05 mM MgCl 2 , 10 mM LiCl, and various concentrations of GABA and gabapentin (from Sigma-Aldrich or Goedecke). The reactions were stopped by exchanging the buffer with 200 l of ice-cold 20 M formic acid, and separation of total [ 3 H]inositol phosphates was carried out by ion-exchange chromatography as described previously (Nanevicz et al., 1996; Brä uner-Osborne et al., 1999a) .
[ 3 H]GABA Filtration Binding Assay. Rat synaptic membranes were prepared using the method described by Zukin et al. (1974) , with some modifications. Whole brains from Sprague-Dawley male rats (about 300 g) were homogenized in 10 volumes of ice-cold buffer containing 0.32 M sucrose, 10 mM Tris, 0.1 mM AEBSF, and 20 g/ml bacitracin, pH 7.4. The homogenate was centrifuged at 1,000g for 10 min, and the supernatant was then centrifuged at 20,000g for 20 min. The pellet was resuspended (by vortex) in 6 volumes of ice-cold distilled water containing 0.1 mM AEBSF and 20 g/ml bacitracin (pH set to 7.4), and centrifuged at 8,000g for 20 min. The supernatant and the upper layer of the pellet were centrifuged at 33,000g for 20 min. The pellet was resuspended in 6 volumes of 50 mM Tris, pH 7.4, containing 1 mM AEBSF and 20 g/ml bacitracin and centrifuged at 33,000g for 20 min. The last centrifugation step was repeated one more time, and finally the pellet was snap-frozen in methanol/dry ice and stored overnight at Ϫ70°C. The frozen pellet was thawed and washed six times in 6 volumes of 50 mM Tris, pH 7.4, by centrifugation at 8,000g for 10 min at 18°C. The resulting pellet was resuspended in TC buffer (50 mM Tris/2.5 mM CaCl 2 , pH 7.4), snap-frozen in methanol/dry ice, and stored at Ϫ70°C. Membranes to be used in the radioligand binding assay were further treated (washed) as follows. The membranes were thawed in lukewarm water followed by resuspension in TC buffer and homogenization using a Polytron PT 3000 from Kinematika AG (Basel, Switzerland) five times for 5 s each. The membranes were washed three times in TC buffer by centrifugation at 8,000g for 10 min, resuspended in TC buffer, and homogenized 10 times in a Teflon/glass homogenizer. The membranes were suspended in aliquots, snapfrozen in methanol/dry ice, and stored at Ϫ70°C. Protein concentration was determined according to the method of Bradford (1976) using the Bio-Rad protein assay kit with bovine ␥-globulin as a standard.
The [ 3 H]GABA competition assay, modified from the method of Olpe et al. (1990) , was performed in 96-well plates in 200 l of TC-isoguvacine buffer (TC buffer supplemented with 40 M isoguvacine to saturate the GABA A receptor sites) containing 20 nM [ 3 H]GABA (3.48 TBq/mmol), 80 l of test compound (at indicated concentrations, diluted in water), and 80 g of synaptic membrane (diluted in TC-isoguvacine buffer) and incubated for 10 min at room temperature before addition). The mixture was then incubated on a microplate shaker (Denley Instruments, Billinghurst-West Sussex, UK) for 20 min at room temperature, followed by rapid filtration through a glass fiber filter (Printed Filtermat B filters; PerkinElmer Wallac, Gaithersburg, MD) that had been presoaked in 0.3% polyethyleneimine, followed by a wash with TC buffer using a Tomtec cell harvester (Tomtec, Orange, CT). The filters were dried in a microwave at maximal effect for 1.5 min followed by incubation at 55°C for 45 min. MeltiLex B/HS scintillation sheets from PerkinElmer Wallac (Turku, Finland) were melted onto the filter, and radioactivity was determined in a Microbeta scintillation counter (PerkinElmer Wallac).
Measurements of TLESRs in Dogs. TLESRs were measured in adult Labrador retriever dogs using Dentsleeve manometry as described previously . Gabapentin (20 mg/kg) was administered directly into the stomach through the manometric assembly. Thirty minutes after administration, TLESRs were stimulated by liquid nutrient infusion and air insufflation and quantitated during a 45-min period. The effect of the compound was compared with the average of the five preceding control experiments for each individual dog. Gabapentin used for these experiments was obtained from Neurontin capsules (Pfizer), and a suspension was made in 0.9% NaCl immediately before the experiment.
Chemical Analyses of Gabapentin. Melting points of the gabapentin samples obtained from Sigma-Aldrich and Goedecke were determined in capillary tubes.
1 H NMR spectra of both samples were recorded on a 300-MHz Varian Gemini-2000 BB spectrometer (Varian, Palo Alto, CA) in CD 3 OD using the solvent residual peak as internal standard. Elemental analyses of the same gabapentin samples were performed at the Department of Physical Chemistry, University of Vienna, Austria, and were within Ϯ0.4% of the theoretical values for zwitterionic gabapentin.
HPLC analyses of the gabapentin sample from Sigma-Aldrich were performed on a Knauer Vertex Spherisorb ODS2 column (5 m, 4.0 ϫ 120 mm) using a TSP HPLC system (Bie & Berntsen A/S, Copenhagen, Denmark) consisting of a P2000 pump, an AC 3000 autoinjector, and an SM 5000 PDA detector. The column was eluted at 1.0 ml/min with aqueous trifluoroacetic acid, pH 2.0.
Results
We first attempted to reproduce the reported agonistic effects of gabapentin under the same experimental conditions as Ng et al. (2001) . GABA (2.5 M) elicited a solid response at both rat GABA B(1a,2) and GABA B(1b,2) heterodimers expressed in X. laevis oocytes together with K ϩ channel Kir3 subunits (Fig. 1A, inset) . In contrast, application of 1 mM gabapentin (extracted from Neurontin capsules or the pure compound provided by Goedecke) did not give rise to any response (Fig. 1) . Both samples of gabapentin were tested as agonists as well as antagonists at GABA B(1a,2) and GABA B(1b,2) , and no significant change of control was obtained in any of the experiments (Fig. 1) . Ng et al. (2001) found gabapentin to exhibit an efficacy at the GABA B(1a,2) heterodimer similar to that of baclofen and determined the EC 50 value of gabapentin at this heterodimer to be 15 M.
We also compared responses of human and rat GABA B (Fig. 2, A and B). These small responses could be antagonized with CGP54626 (data not shown). GABA activated both heterodimers with EC 50 values in the low micromolar range (Fig. 2, A and B) . To investigate whether gabapentin had modulatory or antagonistic effects at GABA B receptors, it was tested in the presence of 3 M GABA as well. In these experiments, gabapentin displayed neither antagonistic nor positive modulatory properties on GABA B(1a,2) or GABA B(1b,2) (Fig. 2, C and D) . The agonistic properties of GABA and gabapentin on GABA B receptor-dependent release of intracellular calcium were also characterized in CHO-K1 cells stably expressing the human GABA B(1a,2) heterodimer. GABA stimulated intracellular calcium release in these cells with an EC 50 of 380 Ϯ 32 nM (n ϭ 3), whereas gabapentin (up to 1 mM as the final concentration) had no effect on the calcium release (data not shown). A similar result was obtained in CHO cells stably expressing a GABA B(1a) -Gqi5 fusion protein and GABA B(2) . Despite the high potency of GABA (EC 50 ϭ 180 Ϯ 34 nM; n ϭ 3), gabapentin showed no effect at concentrations up to 1 mM (data not shown).
To investigate further the lack of agonistic effects of gabapentin on GABA B receptors, we characterized the compound in an assay for Ca 2ϩ mobilization in a continuous perfusion chamber using fura-2-loaded cells. In this fluorometry assay, 10 mM gabapentin (from Goedecke) elicited weak agonistic responses in HEK 293 cells expressing the GABA B(1a,2) or GABA B(1b,2) heterodimer together with the chimeric G-protein Gq-zic (Fig. 3A) . The agonist response in GABA B(1a,2) -transfected cells could be antagonized with CGP54626 (Fig.  3A) . GABA activated both heterodimers (Fig. 3B) .
Because the FLIPR and fluorometer assays are sensitive to rapid but not to slow changes in [Ca 2ϩ ] i , we also characterized the effects of gabapentin on GABA B receptors in a traditional second-messenger assay (Fig. 4) . In the inositol phosphate (IP) assay, the GABA B(1) and GABA B(2) subunits are coexpressed with the chimeric G-protein G␣q-z5, which enables us to measure GABA B receptor function as IP accumulation (Brä uner-Osborne and Krogsgaard-Larsen, 1999) . In this assay GABA displayed EC 50 values of 3.2 Ϯ 0.5 M at GABA B(1a,2) and 3.5 Ϯ 0.7 M at GABA B(1b,2) (n ϭ 3 in both cases). In contrast to the effects of GABA, no response was observed in cells transfected with GABA B(1a,2) or GABA B(1b,2) upon application of gabapentin (from Sigma-Aldrich or Goedecke) in concentrations up to 100 mM (Fig. 4) .
Gabapentin has previously been reported not to influence radioligand binding to native GABA B receptors (Taylor, 1995; Taylor et al., 1998) . To verify this, we characterized the effects of the compound on [ 3 H]GABA binding to GABA B receptor sites in rat brain membranes in an assay in which the GABA A receptor sites were blocked by coincubation with 40 M isoguvacine (Fig. 5) . Gabapentin (in concentrations up to 1 mM) did not have any effect on the [ 3 H]GABA binding, whereas the IC 50 for GABA was 90 Ϯ 16 nM (n ϭ 3).
For the functional assessment of gabapentin on native GABA B receptors, we investigated the well documented inhibition of TLESR by activation of GABA B receptors at the vagal afferent pathway. At 20 mg/kg, gabapentin did not significantly affect TLESRs in dogs. The average inhibition was 14 Ϯ 23% of controls (n ϭ 4). Likewise, in two experiments in which gabapentin was given i.v. at 50 mg/kg, there was no effect on TLESRs (11% inhibition and 17% stimulation, respectively).
To exclude the possibility that our negative findings arose from testing the wrong compound, we analyzed two of the samples used in the functional assays described above. Melting point determinations and elemental analyses of the gabapentin samples from Sigma-Aldrich and Goedecke were performed and found to be in agreement with the data expected Gabapentin and "Neurontin" (gabapentin extracted from Neurontin capsules) had no effects on X. laevis oocytes expressing rat GABA B(1a,2) or GABA B(1b,2) heterodimers and Kir3 channels. A, Neurontin showed no clear dose-dependent antagonistic effects in oocytes expressing GABA B(1a,2) (Ⅺ, solid line) or GABA B(1b,2) (, dotted line). The linear reduction in the response probablyis caused by a run-down of the response. Neither Neurontin (GABA B(1a, 2) , f, solid line; GABA B(1b,2) , OE, dotted line) nor gabapentin (GABA B(1a,2) , छ; GABA B(1b,2) , ) showed an agonistic activity in oocytes. The effects at 10 Ϫ3 M (indicated by circled B) are shown at a different scale in B. Data were normalized to the GABA EC 80 response (I 0 ). For the GABA B(1a,2) and the GABA B(1b,2) heterodimers, the GABA concentrations used were 5.38 M and 2.52 M, respectively. Inset, a current record at Ϫ70 mV from an oocyte expressing GABA B(1b,2) and Kir 3.1/2/4 channels. Bars indicate the application of GABA (2.5 M), Neurontin (Neu, 1 mM), and gabapentin (GP, 1 mM) . B, no agonistic effects of Neurontin and gabapentin were observed at 1 mM (n ϭ 3) in oocytes.
for zwitterionic gabapentin (Satzinger, 1994) . Furthermore, 1 H NMR spectra of both batches were identical to those previously reported (Griffiths et al., 1991) , thus confirming the authenticity of the gabapentin samples used. Under the conditions used in the HPLC analyses, GABA eluted almost at the front (retention time ϭ 1.3 min). Based on peak areas, at 200 nm, of peaks eluting with retention time Ͻ 1.5 min, the gabapentin sample from Sigma-Aldrich contained less than 4% (w/w) (detection limit) of GABA.
Discussion
The recent cloning of GABA B(1) and GABA B(2) has brought about a substantially better understanding of the pharmacology and medicinal chemistry aspects of the GABA B receptors (Kaupmann et al., 1997 (Kaupmann et al., , 1998 Jones et al., 1998; White et al., 1998) . The majority of GABA B receptors exist as either GABA B(1a,2) or GABA B(1b,2) heterodimers (Benke et al., 1999; Prosser et al., 2001; Schuler et al., 2001) , and the wish to understand the physiological roles of these two heterodimers has prompted the search for GABA B(1) splice variant-selective ligands. Considering that the VFT domain responsible for binding of the endogenous agonist is conserved within the GABA B(1) splice variants, this quest has seemed to be quite difficult. Recently, however, the anticonvulsant drug gabapentin was claimed to be a selective agonist at the GABA B(1a,2) heterodimer with an EC 50 value in the low micromolar range Ng et al., 2001 ). We were puzzled by the proposed involvement of regions outside of the VFT region in the binding of gabapentin, considering its GABAtemplate, and decided to verify the data.
In our hands, gabapentin did not display any agonistic effects at either rat or human variants of the GABA B(1a,2) or the GABA B(1b,2) heterodimer, when characterized by means of electrophysiology in oocytes (up to 1 mM), in FLIPR experiments (up to 1 mM), or in an IP assay (up to 100 mM). The only gabapentin responses we observed were in the FLIPR and fluorometer assays of transiently transfected HEK 293 cells at concentrations of 10 mM. These weak agonistic responses took place at a concentration 1,000-to 10,000-fold higher than the concentrations used by Ng and coworkers to obtain an effect ( Fig. 2A) Ng et al., 2001) and is much too high to explain the therapeutic benefits of the compound. Furthermore, these effects of gabapentin were observed for both the GABA B(1a,2) and the GABA B(1b,2) heterodimers; thus, it was clearly not a receptor splice variant-specific effect. A 1:10,000 contamination of gabapentin with GABA would be sufficient to elicit these responses. We cannot exclude the possibility, given the purity profiles of the gabapentin samples obtained from the chemical analyses, that the agonist responses are Fig. 2 . Comparison of the effects of GABA and gabapentin on human GABA B(1a,2a) and GABA B(1b,2a) heterodimers in the FLIPR. Concentrationresponse curves of GABA (F) and gabapentin (E) tested for agonism at GABA B(1a,2a) (A) and GABA B(1b,2a) (B) . Data are normalized to the average response of 10 Ϫ4 M GABA; error bars are S.E.M. from quadruplicate determinations. Lines are weighted fits of Hill equations to the data points. EC 50 values are 3.5 (2.6, 4.8) M and 4.6 (2.7, 7.9) M for GABA B(1a,2a) and GABA B(1b,2a) , respectively (mean; lower and upper 95% confidence interval). Antagonism of gabapentin (E) against 3 M GABA at human GABA B(1a,2a) (C) and GABA B(1b,2a) (D). Data are normalized to the response induced by 3 M GABA alone, and error bars are S.E.M. from quadruplicate determinations. The results from the functional in vitro assays are supported by the lack of inhibition displayed by gabapentin in the TLESR model. It is well documented that GABA B receptor agonists are powerful inhibitors of TLESRs in dogs , ferrets (Blackshaw et al., 1999) , and humans (Lidums et al., 2000) . Although the identity of the splice variant(s) mediating this effect has (have) not been determined, it is likely that GABA B(1a) plays an important role. This assumption rests on the observation that high levels of GABA B(1a) are found in the canine nodose ganglion (J. Ekstrand, N. Poorkhalkali, and A. Lehmann, unpublished observations) supplying vagal afferents that represent the major site of action with regard to inhibitory effects on TLESRs of GABA B receptor agonists (Partosoedarso et al., 2001) . Hence, the observation that gabapentin does not inhibit TLESRs in dogs indirectly supports the notion that gabapentin does not activate the native GABA B(1a,2) heterodimer. Ng et al. (2001) used recombinant human and murine GABA B receptors in their study of gabapentin. The experiments in the present study were performed on recombinant rat and human receptors (summarized in Table 1 ). We do not have the murine mIL-tsA58 cell line, in which gabapentin is reported to have inhibited the high K ϩ -evoked calcium mobilization ), nor have we tested the effects of gabapentin at recombinant murine GABA B receptors. A comparison of the amino acid sequence of the Sushi domains in the rat, human, and murine GABA B(1a) B(1a,2) and GABA B(1b,2) heterodimers and G␣q-z5. Three individual experiments were performed in triplicate as described under Experimental Procedures. Ⅺ, GABA at GABA B(1a,2) ; E, GABA at GABA B(1b,2) ; f, gabapentin at GABA B(1a,2) ; and F, gabapentin at GABA B(1b,2) . Data are given as disintegration per minute (DPM) per well, and lines are weighted fits of Hill equations to the data points. Gabapentin from Sigma-Aldrich was also inactive at GABA B(1a,2) and GABA B(1b,2) heterodimers in concentrations up to 100 mM (data not shown). B(1a) . The first three of these five residues are located in the signal peptides of the receptors and cannot explain any species differences. Because the last two residues are identical in murine and human GABA B(1a) , it is reasonable to assume that gabapentin would be inactive at the murine GABA B(1a,2) heterodimer as well.
Gabapentin Does Not
In principle, the idea that gabapentin is a GABA B receptor agonist is not far-fetched, because GABA B agonists like baclofen and 4-amino-3-(5-chloro-2-thienyl)-butanoic acid possess bulky side chains on the ␤-carbon of their GABA-template. However, because gabapentin does not influence [ 3 H]GABA binding to GABA B receptors in rat brain tissue (Fig. 5) , any putative binding site of the compound clearly is located outside of the endogenous agonist binding pocket in the VFT region of the receptor. If gabapentin were indeed a GABA B(1a,2) -selective agonist, residues in Sushi domains in the amino-terminal domain of GABA B(1a) would have to constitute a major contribution to the binding of the ligand (Kaupmann et al., 1997) . If the binding site of gabapentin were that different from that of the endogenous agonist, the GABA-like structure of gabapentin would have to be purely coincidental.
In conclusion, we have been unable to find agonistic effects of gabapentin on recombinant and native GABA B receptors, as shown by Ng and coworkers ). Gabapentin originating from three different sources has been tested on recombinant rat and human GABA B receptors in three laboratories using five different functional recombinant assays, and in none of these assays have we been able to detect any significant agonistic responses of up to 1 mM gabapentin (Table 1) . In an in vivo model, gabapentin was unable to inhibit TLESRs in dogs, which indirectly supports the notion that the compound is inactive at the GABA B(1a,2) heterodimer. Gabapentin was not active at the GABA B(1b,2) heterodimer either; thus, we find it highly questionable that gabapentin should exert its effects through direct activation of GABA B receptors. In the study by Bertrand et al. (2001) , gabapentin was also reported to be an agonist at native GABA B receptors in neurons of hippocampal slices, where the depression of Ca 2ϩ responses brought on by application of 2 mM gabapentin or 40 M baclofen could be blocked with the GABA B receptor antagonist CGP55845 . In light of the very high concentration of gabapentin used in this experiment, contamination of GABA cannot be ruled out as the explanation for this apparent GABA B effect. Alternatively, indirect effects leading to increased extracellular GABA concentration such as enhanced GABA release, or altered GABA metabolism or uptake inhibition could be the explanation (Taylor et al., 1998) . This could also explain why CGP55845 partially antagonizes the anticonvulsive effect of gabapentin as shown by Cao et al. (2001) . In any case, the mechanism of action for gabapentin remains elusive, and future studies will have to address the basis for the enigmatic anticonvulsant effects of the compound. Furthermore, the first GABA B receptor splice variant-selective ligand remains to be identified.
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